KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Liabilities from Discontinued Operations (2023 - 2025)

Historic Liabilities from Discontinued Operations for Edwards Lifesciences (EW) over the last 3 years, with Q3 2025 value amounting to $2.3 million.

  • Edwards Lifesciences' Liabilities from Discontinued Operations rose 2777.78% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 2777.78%. This contributed to the annual value of $2.0 million for FY2024, which is 9845.56% down from last year.
  • Latest data reveals that Edwards Lifesciences reported Liabilities from Discontinued Operations of $2.3 million as of Q3 2025, which was up 2777.78% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Liabilities from Discontinued Operations ranged from a high of $129.5 million in Q4 2023 and a low of $1.8 million during Q3 2024
  • For the 3-year period, Edwards Lifesciences' Liabilities from Discontinued Operations averaged around $35.3 million, with its median value being $2.3 million (2025).
  • As far as peak fluctuations go, Edwards Lifesciences' Liabilities from Discontinued Operations crashed by 9845.56% in 2024, and later skyrocketed by 2777.78% in 2025.
  • Edwards Lifesciences' Liabilities from Discontinued Operations (Quarter) stood at $129.5 million in 2023, then crashed by 98.46% to $2.0 million in 2024, then rose by 15.0% to $2.3 million in 2025.
  • Its Liabilities from Discontinued Operations stands at $2.3 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.3 million for Q1 2025.